Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 5/20 | 0.44 |
| ▸ | RAF1 | P04049 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 8/20 | 0.43 |
| ▸ | LYN | P07948 | 8/20 | 0.43 |
| ▸ | SRC | P12931 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | HCK | P08631 | 7/20 | 0.43 |
| ▸ | INSR | P06213 | 6/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020220 | 0.94 | MAPK14 (0.47) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3020597 | 0.94 | BRAF (0.46) | MAPK14BRAFRAF1LCKLYN | |
| SCHEMBL3017957 | 0.93 | BRAF (0.47) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3591361 | 0.89 | LMNA (0.48) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3016256 | 0.88 | MAPK14 (0.52) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3594934 | 0.87 | LMNA (0.48) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3015708 | 0.86 | LCK (0.51) | BRAFLCKLYNSRCKDR | |
| SCHEMBL3022247 | 0.85 | LCK (0.53) | BRAFLCKLYNSRCKDR | |
| SCHEMBL3590926 | 0.85 | LMNA (0.46) | LMNANPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL3020035 | 0.85 | LCK (0.59) | BRAFLCKLYNSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | claimed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | claimed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | claimed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | LMNA 3218/4885NPC1 3503/4885RAB9A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.